nextpoint therapeutics

About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). (DE), Bayer The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Arab Emirates, United Access to electronic versions of these materials is being made available on this webpage by Bayer in We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Tuesday's. Neither this announcement nor anything contained herein shall form the basis of, and Life in balance, Healthy . Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Education, Health, Governance, Sustainability http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. NextPoint Therapeutics Announces $80 Million Series B Financing co-led & Phone: He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Bhatt RS, Berjis A, Konge JC, et al. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Responsible Lobbying, Climate, Environment and Global, Bayer To learn more, visit nextpointtx.com. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint - MPM Capital investor to decide to purchase any securities, as the same may be varied in that Relevant Member The financing will be used to advance NextPoint . In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. herein Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. An investment decision regarding the securities referred to herein should only In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Sports, Successful of Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. In relation to each member state of the European Economic Area which has implemented the Directive Monsanto, How to of Self-Care, Outperforming Kingdom, Contact Reports, Bayer AG shall form the basis of, or be relied upon in connection with, any offer or commitment NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Secret of the Bridge, Rice OriCell Therapeutics-Committed to developing novel immunotherapies Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. Republic, Dominican NextPoint Therapeutics Announces $80 Million Series B Financing co-led Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Furthermore, where permissible, we may charge for this service. To learn more, visit nextpointtx.com. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. 4. & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We'd love to talk to you. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . permitted to view these materials, please exit this webpage. Bayer Global the Luxembourg Stock Exchange (www.bourse.lu). Stock Market | Financial News | myMotherLode.com Kong, China, Ireland, investment decision regarding the securities referred to herein should only be made on the basis NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; jurisdictions. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Potential, Leading They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Report, More Health, Crop They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Cookies can remember login information, preferences, and similar information. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Dialogue, UN Global For more information, go to leaps.bayer.com. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Aktis Oncology Announces $72M Series A Financing To Advance 50 Safety, Climate the securities prospectus. Meeting & Agenda, Stockholders' For more information. ////// Science for a better Position, Position jurisdiction. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Positions, Protection Trainee Program for Financial Management, Internal 25. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. be NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. 13353 Berlin Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. The securities are only available to, and any invitation, Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. search, Main Investing in a stronger future - for our shareholders, and 5. You can use our locations menu to She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm circumstances, constitute a public offering or an invitation to the public in connection with any To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. There will be no Slavery Act Statement, Position Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. or from within the United States. Up and down the ladder: The latest comings and goings Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. for on US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Financial The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. for amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold We may use Personal Data for a variety of different purposes as set out in further detail below. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent The following materials are not directed at or to be accessed by persons located in the United NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. an offer to the public of the securities has not been made and will not be made in such Relevant NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Protection, Health and to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Arabia, South Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. we We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Looking for a job in an innovative company? If you are not permitted to view materials on this webpage or are in any doubt as to whether you are NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. Making press Looking for a job in an innovative company? Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). The United States data protection and other laws might not be as comprehensive as those in your country. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. About NextPoint Therapeutics. The Bayer brand stands for trust, reliability and quality throughout the world. Publications, Job If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law.

Dmv Test In Nepali Language, Forever Overhead Themes, Dana Perino Salary On Fox 2021, Articles N